Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
WT1
REST API REST API
Homo sapiens
WT1 is differentially expressed in 239 experiments: 151 organism parts: kidney, ovary, ... (149 more);, 156 disease states: normal, Huntington's disease, ... (154 more);, 79 cell types 431 cell lines 30 compound treatments and 71 other conditions.
Synonyms WIT-2, AWT1, WAGR, GUD
Orthologs FZF1 (Saccharomyces cerevisiae)   wt1a (Danio rerio)   wt1b (Danio rerio)   Wt1 (Mus musculus)   WT1 (Gallus gallus)   Wt1 (Rattus norvegicus)   Cf2 (Drosophila melanogaster)   wt1 (Xenopus laevis)   WT1 (Canis familiaris)   WT1 (Bos taurus)   (Compare orthologs)
Gene Ontology Term negative regulation of cell growth, RNA splicing, negative regulation of transcription, DNA-dependent, protein binding, nuclear speck, regulation of transcription, DNA-dependent, cytoplasm, double-stranded DNA binding, intracellular, negative regulation of cell proliferation, transcription, DNA-dependent, sex determination, negative regulation of apoptosis, male genitalia development, metal ion binding, nucleic acid binding, male gonad development, gonad development, sequence-specific DNA binding, induction of apoptosis, positive regulation of transcription from RNA polymerase II promoter, tissue development, nucleus, heart development, germ cell development, nucleoplasm, negative regulation of transcription from RNA polymerase II promoter, regulation of transcription from RNA polymerase II promoter, negative regulation of translation, positive regulation of transcription, DNA-dependent, RNA binding, nucleolus, zinc ion binding, posterior mesonephric tubule development, positive regulation of heart growth, cellular response to cAMP, glomerular basement membrane development, cellular response to gonadotropin stimulus, kidney development, branching involved in ureteric bud morphogenesis, visceral serous pericardium development, mesonephros development, diaphragm development, adrenal gland development, metanephric S-shaped body morphogenesis, C2H2 zinc finger domain binding, metanephric epithelium development, glomerular visceral epithelial cell differentiation, vasculogenesis, metanephros development, glomerulus development, camera-type eye development, negative regulation of metanephric glomerular mesangial cell proliferation, mesenchymal to epithelial transition, ureteric bud development, epithelial cell differentiation, metanephric ureteric bud development, sequence-specific DNA binding transcription factor activity, negative regulation of female gonad development, metanephric mesenchyme development, transcription regulatory region DNA binding, regulation of organ formation, positive regulation of male gonad development, RNA polymerase II core promoter proximal region sequence-specific DNA binding transcription factor activity involved in positive regulation of transcription, adrenal cortex formation, cardiac muscle cell fate commitment, thorax and anterior abdomen determination
InterPro Term Znf_C2H2-like, Znf_C2H2, Wilms_tumour, Wilms_tumour_N
Gene-Disease Assocation WILMS TUMOR, ANIRIDIA, GENITOURINARY ANOMALIES, AND MENTAL RETARDATION, MEACHAM SYNDROME, FRASIER SYNDROME, DENYS-DRASH SYNDROME; DDS, WILMS TUMOR 1; WT1, NEPHROTIC SYNDROME, TYPE 4; NPHS4, MESOTHELIOMA, MALIGNANT
UniProt Accession A8MN20, Q6PI38, Q6LBI3, B3KSA5, P19544, A0FJ57, A0FJ58, E9PPW3, E9PKS2, E9PMK7, E9PP08
Search EB-eye ENSG00000184937
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-AFMX-5, E-GEOD-6573, E-MEXP-1251, E-MTAB-24, ... (21 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-18005, ... (43 experiments)

Factor Value U/D Experiments
SW480
4
E-GEOD-18005, E-MEXP-1014, E-GEOD-2509, E-MTAB-37
HL-60
3
E-GEOD-5258, E-MTAB-37, E-GEOD-24147
A549
2
E-GEOD-3202, E-GEOD-6013
DU145
2
E-GEOD-17482, E-GEOD-20089
Jurkat
2
E-MEXP-2197, E-MTAB-62
K562
2
E-MTAB-37, E-GEOD-24147
425 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-MEXP-66, E-GEOD-13909, ... (40 experiments)

Factor Value U/D Experiments
iPSC derived from hASC using lentiviral reprogramming vector
1
E-GEOD-20033
iPS cells from episomal vectors (Defined Factor)
1
E-GEOD-20033
pro B cell
1
E-MEXP-1403
epithelioid malignant mesothelioma (MM)
1
E-GEOD-21750
epithelial cells
1
E-GEOD-20758
secretory cell
1
E-GEOD-3998
73 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MTAB-62, E-MTAB-680, ... (54 experiments)

Factor Value U/D Experiments
acute lymphoblastic leukemia
3
E-MTAB-62, E-GEOD-96, E-MTAB-37
chronic myelogenous leukemia
3
E-MTAB-37, E-GEOD-5550, E-MTAB-62
cervical carcinoma
2
E-MTAB-37, E-MTAB-62
lung carcinoma
2
E-MTAB-37, E-GEOD-6014
prostate carcinoma
2
E-MTAB-62, E-MEXP-2034
uterine fibroid
2
E-GEOD-7307, E-MTAB-62
150 more value(s).


Compound treatment

studied in E-GEOD-6907, E-TABM-782, E-GEOD-5824, E-TABM-868, E-GEOD-15811, ... (19 experiments)

Factor Value U/D Experiments
vanadium pentoxide
1
E-GEOD-5339
keratinocyte growth factor
1
E-GEOD-7216
1,25-dihydroxyvitamin D3
2
1
E-GEOD-995
4-hydroxytamoxifen
2
1
E-MEXP-2241
ethanol
1
E-MEXP-2241
DMSO
1
1
E-MEXP-1561
24 more value(s).


Age at diagnosis

studied in E-GEOD-3494

Factor Value U/D Experiments
90
1
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd34
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-GEOD-1729

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-MEXP-1251, E-GEOD-1563, ... (7 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-3140, E-GEOD-4667, E-MEXP-958, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-7788, E-GEOD-2509, E-TABM-147, ... (7 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Genetic modification
studied in E-GEOD-7011, E-MEXP-1482, E-GEOD-7578, E-MTAB-108, E-MEXP-2340 ... (5 experiments)

Genotype
studied in E-TABM-1029, E-MEXP-149, E-GEOD-2466, E-GEOD-17476, E-GEOD-21750, ... (10 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-MEXP-1446, E-MEXP-1741, E-MEXP-2146, E-GEOD-20505 ... (5 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-2466, E-GEOD-1926, E-MEXP-2069, ... (25 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-12662

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-21750, E-GEOD-1460, E-GEOD-3407, E-GEOD-17636, E-MEXP-1403 ... (5 experiments)

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-1343

Qpcr egfr dct
studied in E-GEOD-5851

Qrt pcr areg dct
studied in E-GEOD-5851

RNAi
studied in E-GEOD-12438, E-MEXP-101, E-GEOD-3697, E-MEXP-1857

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

Sex
studied in E-GEOD-2466, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-20114

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Treatment
studied in E-GEOD-16837, E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Processing time: 0.353 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM